Opus Genetics (IRD) Stock Price, News & Analysis

Company Overview

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Key Stats

• Today's Range: $1.75 to $1.83
• 50-Day Range: $1.06 to $1.82
• 52-Week Range: $0.65 to $1.87
• Volume: 242,886 shs
• Average Volume: 508,405 shs
• Market Capitalization: $107.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Buy

Opus Genetics Stock Analysis - MarketRank™

Opus Genetics scored higher than 46% of companies evaluated by MarketBeat, and ranked 638th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Opus Genetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Opus Genetics has a consensus price target of $7.33, representing about 307.4% upside from its current price of $1.80.

Amount of Analyst Coverage

Opus Genetics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Opus Genetics are expected to grow in the coming year, from ($1.22) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Opus Genetics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Opus Genetics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Opus Genetics has a P/B Ratio of 8.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.40% of the float of Opus Genetics has been sold short.

Short Interest Ratio / Days to Cover

Opus Genetics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Opus Genetics has recently increased by 66.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Opus Genetics does not currently pay a dividend.

Dividend Growth

Opus Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.40% of the float of Opus Genetics has been sold short.

Short Interest Ratio / Days to Cover

Opus Genetics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Opus Genetics has recently increased by 66.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.52

News Sentiment

Opus Genetics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Opus Genetics this week, compared to 2 articles on an average week.

Search Interest

15 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

MarketBeat Follows

1 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Opus Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of Opus Genetics is held by insiders.

Percentage Held by Institutions

Only 14.97% of the stock of Opus Genetics is held by institutions.

IRD Stock Analysis - Frequently Asked Questions

How have IRD shares performed this year?

Opus Genetics' stock was trading at $1.19 at the beginning of 2025. Since then, IRD stock has increased by 51.3% and is now trading at $1.80.

How were Opus Genetics' earnings last quarter?

Opus Genetics, Inc. (NASDAQ:IRD) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.13. The business had revenue of $2.88 million for the quarter, compared to the consensus estimate of $4.27 million. Opus Genetics had a negative trailing twelve-month return on equity of 384.33% and a negative net margin of 377.89%.

How do I buy shares of Opus Genetics?

Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IRD
• Previous Symbol: NASDAQ:IRD
• CIK: 1228627
• Web: www.ocuphire.com
• Phone: 248-957-9024
• Fax: 240-268-5310
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Opus Genetics: $7.33
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +307.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.53 million
• Net Margins: -377.89%
• Pretax Margin: -377.89%
• Return on Equity: -384.33%
• Return on Assets: -148.90%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 1.90
• Quick Ratio: 1.90

Sales & Book Value

• Annual Sales: $10.99 million
• Price / Sales: 9.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 8.57

Miscellaneous

• Outstanding Shares: 59,910,000
• Free Float: 55,954,000
• Market Cap: $107.84 million
• Optionable: N/A
• Beta: 0.11